COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,741 Articles (22,502 medRxiv, 8,239 bioRxiv)

Most recent first Previous |  Page 1384: Articles 13831-13840  | Next

Predicting the mutational drivers of future SARS-CoV-2 variants of concern
Maher, M. C., Bartha, I., Weaver, S., Di Iulio, J., Ferri, E., Soriaga, L., Lempp, F. A., Hie, B. L., Bryson, B., Berger, B., Robertson, D. L., Snell, G., Corti, D., Virgin, H. W., Kosakovsky Pond, S., Telenti, A.
10.1101/2021.06.21.21259286 — Posted: 2021-06-22 Discussion: Onsite
Efficacy of Proxalutamide in Hospitalized COVID-19 Patients: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design Clinical Trial
Cadegiani, F. A., Fonseca, D. N., McCoy, J., Zimerman, R. A., Mirza, F. N., Correia, M. N., Barros, R. N., Onety, D. C., Israel, K. C. P., Almeida, B. G., Guerreiro, E. O., Medeiros, J. E. M., Nicolau, R. N., Nicolau, L. F., Cunha, R. X., Barroco, M. F. R., da Silva, P. S., Ferreira, G. S., Alcantara, F. R. P., Ribeiro, A. M., de Almeida, F. O., de Souza, A. A., do Rosario, S. S., Paulain, R. W., Reis, A., Li, M., Thompson, C. E., Nau, G. J., Wambier, C. G., Goren, A.
10.1101/2021.06.22.21259318 — Posted: 2021-06-22 Discussion: Onsite | Offsite
Effectiveness of Tocilizumab, Sarilumab, and Anakinra for critically ill patients with COVID-19 The REMAP-CAP COVID-19 Immune Modulation Therapy Domain Randomized Clinical Trial
Derde, L. P. G., The REMAP-CAP Investigators
10.1101/2021.06.18.21259133 — Posted: 2021-06-22
Integrative analysis of multi-omics reveals gene regulatory networks across brain regions from risk variants to phenotypes of Alzheimer's disease and Covid-19
Khullar, S., Wang, D.
10.1101/2021.06.21.449165 — Posted: 2021-06-22
The polarity and specificity of SARS-CoV2 -specific T lymphocyte responses determine disease susceptibility
FAHRNER, J.-E., CARRIER, A., Lyon COVID study group, , DE SOUSA, E., DRUBAY, D., DUBUISSON, A., GERAUD, A., GOUBET, A.-G., FERRERE, G., HADDAD, Y., LAHMAR, I., MAZZENGA, M., MELENOTTE, C., PICARD, M., THELEMAQUE, C., CERBONE, L., LERIAS, J. R., LAPARRA, A., BERNARD, A., KLOECKNER, B., GAZZANO, M., DANLOS, F.-X., TERRISSE, S., ALVES COSTA SILVA, C., PIZZATO, E., FLAMENT, C., LY, P., TARTOUR, E., MEZIANI, L., AHMED-BELKACEM, A., MIYARA, M., Gorochov, G., BARLESI, F., PRADON, C., GALLOIS, E., POMMERET, F., COLOMBA, E., LAVAUD, P., DEUTSCH, E., GACHOT, B., SPANO, J.-P., Merad, M., SCOTTE, F., MARABELLE, A., GRISCELLI, F., BLAY, J.-Y., SORIA, J.-C., ANDRE, F., Chevalier, M., CAILLAT-ZUCMAN, S., FENOLLAR, F., LA SCOLA, B., KROEMER, G., MAEURER, M., DEROSA, L., ZITVOGEL, L.
10.1101/2021.06.18.21258477 — Posted: 2021-06-22
The challenge of structural heterogeneity in the native mass spectrometry studies of the SARS-CoV-2 spike protein interactions with its host cell-surface receptor
Yang, Y., Ivanov, D. G., Kaltashov, I. A.
10.1101/2021.06.20.449191 — Posted: 2021-06-21
Spatial transcriptomic characterization of COVID-19 pneumonitis identifies immune pathways related to tissue injury
Cross, A. R., de Andrea, C., Landecho Acha, M., Cerundolo, L., Etherington, R., Denney, L., Ho, L.-P., Roberts, I., Klenerman, P., Hester, J., Melero, I., Sansom, S., Issa, F.
10.1101/2021.06.21.449178 — Posted: 2021-06-21
One viral sequence for each host? - The neglected within-host diversity as the main stage of SARS-CoV-2 evolution
Ruan, Y., Hou, M., Li, J., Song, Y., Wang, H.-Y., Zeng, H., Lu, J., Wen, H., Chen, C., Wu, C.-I.
10.1101/2021.06.21.449205 — Posted: 2021-06-21
The green tea catechin EGCG provides proof-of-concept for a pan-coronavirus entry inhibitor
LeBlanc, E. V., Colpitts, C. C.
10.1101/2021.06.21.449320 — Posted: 2021-06-21
Immunological features that determine the strength of antibody responses to BNT162b2 mRNA vaccine against SARS-CoV-2
Kageyama, T., Tanaka, S., Etori, K., Hattori, K., Miyachi, K., Kasuya, T., Iwamoto, T., Ikeda, K., Igari, H., Yokote, K., Nakajima, H.
10.1101/2021.06.21.449182 — Posted: 2021-06-21

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).